trial

Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

NCTId NCT04529226
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 75 (actual)
Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Primary completion 2025-01-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
75 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2020-11-26
Primary completion
2025-01-30
Eligibility
ALL · 16 Years · 55 Years

Interventions & indications

Drugs
ClozapineOlanzapine

Sponsors

Fundación Pública Andaluza para la gestión de la Investigación en SevillaLead Sponsor

Investigators

1
Benedicto Crespo Facorro, ProfessorPrincipal Investigator

Sites

20 total
Andújar, SpainArmilla, SpainCabra, SpainCastril, SpainCórdoba, SpainCórdoba, SpainGranada, SpainGranada, SpainJerez de la Frontera, SpainJerez de la Frontera, SpainJerez de la Frontera, SpainMálaga, Spain

Linked catalysts

1
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Dis — primary completion2025-01-30

Facts & assertions

4 sourced
Enrollment
75
Phase
PHASE2
Primary Completion Date
2025-01-30
Status
UNKNOWN
relationships
The graph out of here
drug
Clozapine
drug
Olanzapine
drug
lead_sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
company
indication
Intellectual Disability
indication
Intellectual Disability
indication
Psychosis
indication
investigator
Benedicto Crespo Facorro, Professor
person